Readers following the Nexavar compulsory licensing story will know that multi-national pharma companies had expected the US to defend their patents. In fact, as the SpicyIP blog notes, the US reaction has been muted. US trade policy is a complex issue but this does seem a surprisingly calm reaction from the world’s foremost protector of IP.
About Us
Health Issues India is a web portal that tracks key health stories and issues in India. On our website, you will find a guide to some of the latest trends, research, reports and journals on health. We provide original interviews and opinions of specialists as well as our own commentary on issues and events.
Newsletter
Subscribe our newsletter to stay updated
Copyright © 2023 | Health Issues India | All rights reserved.
Sorry. This had a bad link in it. Both hyperlinks now point to the correct part of the Spicy IP blog